Answers are grounded in this paper and cite their sources.
The first self-immolative dendritic glucuronide prodrug of doxorubicin was studied with the aim to target β-glucuronidase overexpressed in the microenvironment of numerous tumors. This compound includes a chemical amplifier programmed to release two molecules of doxorubicin after a single enzymatic activation step. Upon β-glucuronidase activation, the dendritic prodrug was twice more toxic than its monomeric counterpart against H661 lung cancer cells.
No takes yet. Share an insight, caveat, or question.
Grinda et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: